Print this page
-
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP- 5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) Rearrangement or Nucleophosmin 1 (NPM1) Mutation.
Protocol: 022303Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Phase 1 Study of Venetoclax/Azacitidine or Venetoclax in Combination with Ziftomenib (KO-539) or Standard Induction Cytarabine/ Daunorubicin (7+3) Chemotherapy in Combination with Ziftomenib for the Treatment of Patients with Acute Myeloid Leukemia.
Protocol: 022305Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials.
Protocol: 022404Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study.
Protocol: 022404-MM1MDS-A0Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia.
Protocol: 022404-MM1OA-EA0Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial).
Protocol: 022404-MM1YA-CTGPrincipal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia.
Protocol: 022404-MM1YA-S01Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Phase II Multicenter Open-label Trial of Tagraxofusp (Tag) in Combination With Venetoclax and Azacitidine (Ven/Aza) in Adults With Previously Untreated CD123+ Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy.
Protocol: 022405Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other -
A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination with ASTX727 in Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Protocol: 022503Principal Investigator:
- Neil Palmisiano
Applicable Disease Sites: Leukemia, other
Myeloid and Monocytic Leukemia -
A Randomized Phase II Trial of Adjuvant Pembrolizumab versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors between 1-4 cm.
Protocol: 032006Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Lung -
Biomarkers of Oral Carcinogenesis and Oral Cancer Pain
Protocol: 032202Applicable Disease Sites: Lip, Oral Cavity and Pharynx
-
Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx -
Preoperative Plasma ctDNA Detection in Early Stage Cancer: A Proof-of-Concept Evaluation
Protocol: 032308Principal Investigator:
- Missak Haigentz
Applicable Disease Sites: Colon
Lung -
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer.
Protocol: 032309Principal Investigator:
- Salma Jabbour
Applicable Disease Sites: Lung